Leprosy never disappeared. More than 180,000 new cases were diagnosed worldwide in 2023, and the number in 2024 was similar, with over 172,000 cases reported across 188 countries. What changed is that leprosy became curable, treatable with a simple combination of antibiotics that can be taken at home. The disease went from a terrifying, disfiguring sentence to a manageable infection, and that transformation pushed it out of public consciousness in wealthier nations even as it persists in parts of Asia, South America, and Africa.
Why Leprosy Faded From Public Awareness
For most of human history, leprosy was one of the most feared diseases on the planet. People diagnosed with it were forcibly isolated in colonies, stripped of legal rights, and treated as spiritually condemned. The stigma was so severe that in 1931, a patient at a US leprosarium began publishing a newsletter advocating that the disease be renamed “Hansen’s disease,” after the Norwegian doctor who identified the bacterium under a microscope in 1873. That push to rebrand the illness was one of the earliest patient-led antistigma campaigns in medicine.
The real turning point came in the 1980s, when the World Health Organization began distributing a combination antibiotic treatment that could cure the disease entirely. Before that, treatment options were limited and slow. With effective drugs available and distributed for free through the WHO, the number of active cases worldwide plummeted from millions to hundreds of thousands within two decades. Countries that once had widespread leprosy brought their prevalence below the threshold the WHO uses to declare a disease no longer a major public health concern. By the early 2000s, most of the world had crossed that line, and leprosy largely vanished from headlines.
How Leprosy Is Cured Today
The standard treatment is a three-drug antibiotic regimen taken for either six or twelve months, depending on the severity of infection. Milder cases with fewer bacteria need six months. More advanced cases with a higher bacterial load take twelve. The drugs kill the bacterium effectively, and once treatment begins, a person stops being contagious within days. The WHO provides the medication free of charge to every patient in the world, which has been critical in countries where out-of-pocket costs would be a barrier.
This is a dramatic shift from earlier eras. Before antibiotics, there was no cure at all. The disfigurement historically associated with leprosy, the loss of fingers or toes, the collapse of nasal cartilage, happened because the disease went untreated for years or decades, slowly destroying nerve tissue. Today, catching it early and starting treatment prevents nearly all of that damage.
What Leprosy Actually Does to the Body
Leprosy is caused by a slow-growing bacterium that primarily attacks the nerves in the skin, hands, feet, and face. The earliest sign is often a discolored patch of skin, lighter than the surrounding area, that has lost sensation. You might not feel a touch or a pinprick in that spot. This numbness is the hallmark of the disease and the source of its worst consequences: when people can’t feel pain in their hands or feet, they injure themselves without realizing it, and those untreated injuries lead to infections, tissue loss, and deformity over time.
The bacterium has an extraordinarily long incubation period. It can take up to 20 years after exposure for symptoms to appear. This makes tracking transmission difficult and means someone can carry the infection for years without knowing it. It spreads through respiratory droplets, similar to tuberculosis, but requires prolonged, close contact with an untreated person. Casual encounters pose essentially no risk. About 95% of people who are exposed never develop the disease at all because their immune systems clear the bacterium naturally.
Where Leprosy Still Persists
Three countries account for the vast majority of new cases. India reported nearly 101,000 new diagnoses in 2024, making it by far the most affected nation. Brazil followed with about 22,000 cases, and Indonesia reported roughly 14,700. Together, these three countries represent around 80% of the global burden. The concentration in specific regions reflects a combination of factors: poverty, crowded living conditions, limited access to early diagnosis, and ongoing stigma that discourages people from seeking care.
The numbers have plateaued in recent years rather than continuing to decline, which concerns public health officials. The remaining cases are the hardest to reach, in remote communities, among marginalized populations, and in places where the stigma of a leprosy diagnosis still carries devastating social consequences.
Leprosy in the United States
The US still sees cases every year, and the trend in some areas is rising. About 159 new cases were reported nationally in 2020, and the southeastern states have seen case numbers more than double over the past decade. Central Florida has become a particular hotspot, accounting for 81% of Florida’s cases and nearly one fifth of all nationally reported cases.
What makes the Florida cluster unusual is that roughly 34% of new patients during 2015 to 2020 had no obvious exposure. They hadn’t traveled to endemic countries, hadn’t been in close contact with a known case, and hadn’t handled armadillos (nine-banded armadillos in the southern US carry the same strain of the bacterium and are a confirmed source of transmission). Many of these patients simply spent a lot of time outdoors in central Florida. Researchers are now investigating whether the bacterium persists in the local environment, in soil or water, as a potential route of infection. The emerging picture suggests that leprosy may have become locally endemic in parts of Florida, meaning it circulates in the environment without needing to be imported from abroad.
The First Vaccine Is Approaching
Despite having an effective cure, the world has never had a vaccine for leprosy. That may be changing. A vaccine called LepVax has completed a Phase 1 clinical trial in the United States, where it was shown to be safe in humans and triggered a strong immune response. In animal studies, the vaccine reduced bacterial levels when given preventively and delayed nerve damage when given after exposure, a finding that matters because many people in endemic areas have already encountered the bacterium by the time they’d be vaccinated.
The next step is a Phase 1b trial in Brazil, testing the vaccine in populations that actually face the disease. If successful, a leprosy vaccine could become the tool that finally breaks transmission in the communities where antibiotics alone haven’t been enough. The challenge has always been that treatment cures individuals but doesn’t prevent new infections. A vaccine would close that gap.
Why It Still Matters
Leprosy occupies a strange place in public perception. Most people think of it as a biblical plague, something that no longer exists. The reality is that it infects hundreds of thousands of people every year, causes permanent disability when caught late, and carries a social stigma so severe that in some countries a diagnosis can mean losing your job, your marriage, or your place in the community. The WHO provides free treatment, but treatment only works if people come forward, and stigma is the single biggest barrier to that.
The disease also remains poorly understood in ways that surprise researchers. No one has successfully grown the bacterium in a lab culture, which limits the ability to study it. The reasons why 95% of people are naturally immune while 5% are vulnerable remain unclear. And the extraordinarily slow incubation period, potentially spanning two decades, makes it nearly impossible to trace where and when someone was infected. Leprosy is curable, but it is not solved.